Revenue generation has effectively ceased, marking a complete reversal from the $48.5 million reported in 2023Q1 while operating losses remain entrenched above $400,000 per quarter.
| Sales/Revenue | 0 | 2.4M | 3.59M | 0 |
| Revenue Growth % | -100% | -33.14% | - | - |
| Cost of Goods Sold | 0 | 1.8M | 1.62M | 0 |
| COGS % of Revenue | - | 75.08% | 45% | - |
| Gross Profit | 0 | 598.93K | 1.98M | 0 |
| Gross Margin % | - | 24.92% | 55% | - |
| Gross Profit Growth % | - | -69.71% | - | - |
| Operating Expenses | 1.67M | 2.95M | 2.51M | 135.65K |
| OpEx % of Revenue | - | 122.93% | 69.89% | - |
| Selling, General & Admin | 1.18M | 1.7M | 26.09M | 135.65K |
| SG&A % of Revenue | - | 70.91% | 725.77% | - |
| Research & Development | 0 | 276.96K | 0 | 0 |
| R&D % of Revenue | - | 11.52% | - | - |
| Other Operating Expenses | 486.92K | 973.43K | -23.58M | 0 |
| Operating Income | -1.67M | -2.36M | -535.45K | -135.65K |
| Operating Margin % | - | -98.01% | -14.9% | - |
| Operating Income Growth % | - | -339.95% | -294.73% | - |
| EBITDA | -1.02M | -1.45M | 363.17K | -119.63K |
| EBITDA Margin % | - | -60.42% | 10.1% | - |
| EBITDA Growth % | -105.79% | -499.89% | 403.58% | - |
| D&A (Non-Cash Add-back) | 0 | 903.44K | 898.63K | 0 |
| EBIT | -1.02M | -2.36M | -535.45K | -119.63K |
| Net Interest Income | -309.16K | -42.84K | -46.61K | 99 |
| Interest Income | 646.66K | 0 | 0 | 99 |
| Interest Expense | 955.82K | 42.84K | 46.61K | 0 |
| Other Income/Expense | -307.62K | -42.84K | -46.61K | 16.02K |
| Pretax Income | -1.98M | -2.4M | -582.06K | -119.63K |
| Pretax Margin % | - | -99.79% | -16.19% | - |
| Income Tax | 132.82K | -7.41K | 147.8K | 0 |
| Effective Tax Rate % | -6.72% | 0.31% | -25.39% | 0% |
| Net Income | -2.11M | -2.3M | -729.16K | -119.63K |
| Net Margin % | - | -95.86% | -20.28% | - |
| Net Income Growth % | -1234.05% | -215.98% | -509.51% | - |
| Net Income (Continuing) | -2.11M | -2.39M | -729.86K | -119.63K |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | -116.19K | -24.93K | 0 |
| EPS (Diluted) | -0.60 | -0.38 | -0.00 | -0.00 |
| EPS Growth % | -1696.72% | - | - | - |
| EPS (Basic) | - | -0.38 | 0.02 | -0.00 |
| Diluted Shares Outstanding | 3.52M | 6.01M | 53.59M | 53.59M |
| Basic Shares Outstanding | 3.52M | 6.01M | 34.45M | 34.45M |
| Dividend Payout Ratio | - | - | - | - |
Critical Liquidity Shortfall
Based on the most recent financial disclosures, ALPS has experienced a total cessation of reported revenue, marking a stark reversal from the $48.5 million in top-line performance observed in 2023Q1 and suggesting a fundamental breakdown in the company's ability to monetize its integrated clinical service model.
The transition from meaningful revenue generation to a complete lack of reported income indicates that the company's transactional business model may have failed to gain traction in the competitive Malaysian healthcare market. Investors should monitor whether this reflects a permanent loss of market share or a temporary disruption in service delivery.
As reported in recent filings, ALPS continues to incur significant operating losses, with quarterly deficits consistently exceeding $400,000 despite the absence of revenue, which highlights an inability to scale down the fixed cost base in response to the total collapse of the top-line.
The persistence of these losses suggests that the company's overhead, likely tied to specialized medical staff and facility maintenance, remains rigid. This lack of operating leverage implies that the current business structure is fundamentally misaligned with its actual market demand.
According to the provided income statement data, the company's net income has swung from a positive $682,900 in 2023Q1 to consistent quarterly losses, indicating that historical profitability was likely transient and not supported by a sustainable, recurring revenue stream or disciplined cost management.
The erratic nature of the bottom line, coupled with the recent absence of revenue, warrants deep skepticism regarding the quality of past earnings. It appears that the company's financial health is highly sensitive to non-operating factors or accounting adjustments that are no longer providing support.
Based on the reported figures, the company's reliance on a high-fixed-cost clinical model without a consistent revenue base creates a precarious situation, as the current cash position of $460,467 appears insufficient to cover ongoing operating losses for more than a few quarters.
Short-sellers would likely focus on the lack of a clear path to break-even and the potential for further dilution or insolvency. The absence of revenue suggests that the 'closed-loop' clinical model may be more of a marketing narrative than a viable, scalable business operation.
Quick answers to the most common questions about buying ALPS stock.
For fiscal year 2023, Alps Group Inc (ALPS) reported total revenue of $2.4M.
Alps Group Inc (ALPS) reported a net loss of $2.3M for the fiscal year ending 2023.
Alps Group Inc (ALPS) reported an operating income of $-2.4M, resulting in an operating profit margin of -98.0%. This margin reflects the operational efficiency of the business before interest and taxes.
Alps Group Inc (ALPS) generated $0.6M in gross profit for the year, representing a gross profit margin of 24.9%. This demonstrates the company's core pricing power and production efficiency.